AGMB

Jun 23, 4:40 PMAgomab announces FDA-aligned design and key regulatory clearances for Phase 2b NOV-ERA study of ontunisertib in fibrostenosing Crohn’s, first dosing in 2H 2026

Peers: INCY KYMR NUVL BMRN RYTM VKTX KRYS AXSM MDGL NBIX

| Held by: SBIO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	25.59%	Shs Outstand	48.74M	Perf Week	31.73%
Market Cap	648.49M	Forward P/E	-	EPS next Y	-2.09	Insider Trans	0.00%	Shs Float	36.26M	Perf Month	20.41%
Enterprise Value	513.12M	PEG	-	EPS next Q	-0.39	Inst Own	22.06%	Short Float	2.18%	Perf Quarter	3.46%
Income	-	P/S	-	EPS this Y	98.92%	Inst Trans	59.65%	Short Ratio	5.90	Perf Half Y	-
Sales	-	P/B	4.22	EPS next Y	-19.00%	ROA	-	Short Interest	0.79M	Perf YTD	-9.18%
Book/sh	3.15	P/C	4.74	EPS next 5Y	76.13%	ROE	-	52W High	17.45 -23.77%	Perf Year	-
Cash/sh	2.81	P/FCF	-	EPS past 3/5Y	-102.05% -	ROIC	-	52W Low	8.75 52.06%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.34% 10.80%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.49	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	67.62	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.49	EPS Q/Q	-	SMA20	20.62%	Beta	-	Target Price	32.28
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	19.45%	Rel Volume	0.55	Prev Close	12.68
Employees	62	LT Debt/Eq	0.01	Earnings	Jun 03	SMA200	8.51%	Avg Volume	134.08K	Price	13.31
IPO	Feb 06, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	3.21% -	Trades		Volume	41,553	Change	4.93%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-22-26	Initiated	H.C. Wainwright	Buy	$35
Mar-03-26	Initiated	Morgan Stanley	Overweight	$28
Mar-03-26	Initiated	Leerink Partners	Outperform	$36
Mar-03-26	Initiated	JP Morgan	Overweight	$32

Jun-23-26 04:05PM	Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease (GlobeNewswire) +6.20%
May-27-26 05:00AM	Agomab Announces Results of Annual General Meeting (GlobeNewswire) +5.61%
May-14-26 07:30AM	Agomab to Participate in Upcoming Conferences (GlobeNewswire)
Apr-23-26 06:14PM	Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook (GlobeNewswire)
Mar-26-26 07:00AM	Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire) -7.70%
04:05PM	Loading…
Feb-09-26 04:05PM	Agomab Announces Closing of Initial Public Offering (GlobeNewswire) +6.55%
Feb-07-26 10:55AM	Agomab indicated to open at $15.50, IPO priced at $16 (TipRanks)
Feb-05-26 07:24PM	Agomab Announces Pricing of Initial Public Offering (GlobeNewswire)

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

Ph.D.Dr. Tim Knotnerus MSc

FounderMr. Paolo Michieli Ph.D.

Chief Financial OfficerMr. Pierre Kemula B.Sc.

Vice President of Investor RelationsSofie Van Gijsel

General CounselMs. Ellen Lefever

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AgomAb Therapeutics NV ADR

Upgrade your Finviz experience